Tirzepatide safety and efficacy assessed in Indian adults with **Type 2 Diabetes** or **Obesity**

Type 2 Diabetes Mellitus (T2DM) and obesity represent significant public health challenges globally, with India experiencing a rapidly increasing burden. Existing treatments often fall short in achieving comprehensive glycemic control, substantial weight loss, and sustained long-term benefits. Tirzepatide, a novel dual GLP-1R and GIPR agonist, has demonstrated superior efficacy in glucose management and weight reduction in diverse populations. This study aims to specifically investigate its safety and effectiveness within the Indian demographic, addressing potential variations in drug response and treatment needs unique to this population.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adult participants in India with either Type 2 Diabetes Mellitus or obesity (or overweight without T2DM) are enrolled. The intervention arm receives tirzepatide once weekly, while the control arm receives placebo. The study duration for each participant is approximately 46 weeks. The primary objectives are to measure the safety and efficacy of tirzepatide in this specific population, though detailed efficacy endpoints (e.g., HbA1c reduction, body weight change) are not specified in this registration.